Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 18/20 | 0.61 |
| ▸ | JAK3 | P52333 | 17/20 | 0.61 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280028 | 0.85 | JAK2 (0.63) | JAK2PTK2JAK3BTK | |
| SCHEMBL17873950 | 0.82 | JAK2 (0.57) | JAK2PTK2JAK3BTKJAK1 | |
| SCHEMBL15173576 | 0.81 | JAK3 (0.79) | JAK2PTK2JAK3BTKJAK1 | |
| SCHEMBL17842598 | 0.81 | JAK3 (0.63) | JAK2PTK2JAK3BTKJAK1 | |
| SCHEMBL23422002 | 0.80 | JAK2 (0.57) | JAK2PTK2JAK3BTKBRD4 | |
| SCHEMBL16370940 | 0.77 | EGFR (0.71) | JAK2JAK3BRD4 | |
| SCHEMBL15453508 | 0.77 | EGFR (0.50) | JAK2PTK2JAK3BTKJAK1 | |
| SCHEMBL2044932 | 0.76 | EGFR (0.71) | JAK2PTK2JAK3BTK | |
| SCHEMBL2640382 | 0.76 | JAK2 (1.00) | JAK2PTK2JAK3JAK1 | |
| SCHEMBL9995228 | 0.76 | EGFR (0.67) | JAK2PTK2JAK3BTKBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | HANMI PHARM. CO., LTD. (KR) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364438-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR | LCK, TYK2, LTK | JAK2 40/4885PTK2 151/4885JAK3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.